Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F.P. and Boulton, D.W. (2011) Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study. Clinical Therapeutics, 33, 1798-1808.
https://doi.org/10.1016/j.clinthera.2011.09.011

has been cited by the following article:

• TITLE: Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review

  AUTHORS: Pedro Luis Imbeth-Acosta, Nehomar Pájaro-Galvis, Víctor Leal-Martinez, Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Orlando Castañeda-López, María Cardona-Blanco, Karen Mercado-Anillo, José Lucas-Daza, Christian Perez-Calvo, Jhonatan Hernández-Meza, Álvaro Barraza-Pombo, Marianela Florez-Ortega, Jorge Hoyos-Fortich, Isabella Uparella-Gulfo

  KEYWORDS: Cirrhosis, Hypoglycemic Agents, Pharmacokinetics (MeSH)

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.10 No.10, October 29, 2020

  ABSTRACT: Chronic liver disease (CLD) refers to a structural and functional change of the liver, which modifies the pharmacokinetics of multiple drugs, including hypoglycemic agents. This alteration depends on the severity degree of the liver disease, clinical characteristics of the patient, and comorbidities presence such as kidney disease and drug biochemistry. Insulin is considered a safe therapeutic strategy in patients with CLD, however, for many oral hypoglycemic agents, its use and dose adjustment will depend on the Child-Pugh score, based on the risk of hypoglycemia in this type of patient.